Use of imaging prediction model for omission of axillary surgery in early-stage breast cancer patients
- PMID: 37097375
- DOI: 10.1007/s10549-023-06952-w
Use of imaging prediction model for omission of axillary surgery in early-stage breast cancer patients
Abstract
Purpose: To develop a prediction model incorporating clinicopathological information, US, and MRI to diagnose axillary lymph node (LN) metastasis with acceptable false negative rate (FNR) in patients with early stage, clinically node-negative breast cancers.
Methods: In this single center retrospective study, the inclusion criteria comprised women with clinical T1 or T2 and N0 breast cancers who underwent preoperative US and MRI between January 2017 and July 2018. Patients were temporally divided into the development and validation cohorts. Clinicopathological information, US, and MRI findings were collected. Two prediction models (US model and combined US and MRI model) were created using logistic regression analysis from the development cohort. FNRs of the two models were compared using the McNemar test.
Results: A total of 964 women comprised the development (603 women, 54 ± 11 years) and validation (361 women, 53 ± 10 years) cohorts with 107 (18%) and 77 (21%) axillary LN metastases in each cohort, respectively. The US model consisted of tumor size and morphology of LN on US. The combined US and MRI model consisted of asymmetry of LN number, long diameter of LN, tumor type, and multiplicity of breast cancers on MRI, in addition to tumor size and morphology of LN on US. The combined model showed significantly lower FNR than the US model in both development (5% vs. 32%, P < .001) and validation (9% vs. 35%, P < .001) cohorts.
Conclusion: Our prediction model combining US and MRI characteristics of index cancer and LN lowered FNR compared to using US alone, and could potentially lead to avoid unnecessary SLNB in early stage, clinically node-negative breast cancers.
Keywords: Axilla; Breast cancer; Lymph nodes; Magnetic resonance imaging; Ultrasound.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Value of Breast MRI and Nomogram After Negative Axillary Ultrasound for Predicting Axillary Lymph Node Metastasis in Patients With Clinically T1-2 N0 Breast Cancer.J Korean Med Sci. 2023 Aug 28;38(34):e251. doi: 10.3346/jkms.2023.38.e251. J Korean Med Sci. 2023. PMID: 37644678 Free PMC article.
-
Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?BMC Surg. 2022 Mar 3;22(1):80. doi: 10.1186/s12893-022-01530-1. BMC Surg. 2022. PMID: 35241059 Free PMC article.
-
Association between US features of primary tumor and axillary lymph node metastasis in patients with clinical T1-T2N0 breast cancer.Acta Radiol. 2018 Apr;59(4):402-408. doi: 10.1177/0284185117723039. Epub 2017 Jul 27. Acta Radiol. 2018. PMID: 28748712
-
Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis.Breast Cancer Res Treat. 2021 Jun;187(2):303-310. doi: 10.1007/s10549-021-06194-8. Epub 2021 Apr 10. Breast Cancer Res Treat. 2021. PMID: 33837870 Review.
-
Axillary Nodal Evaluation in Breast Cancer: State of the Art.Radiology. 2020 Jun;295(3):500-515. doi: 10.1148/radiol.2020192534. Epub 2020 Apr 21. Radiology. 2020. PMID: 32315268
Cited by
-
Integrating Proteomics and Lipidomics for Evaluating the Risk of Breast Cancer Progression: A Pilot Study.Biomedicines. 2023 Jun 22;11(7):1786. doi: 10.3390/biomedicines11071786. Biomedicines. 2023. PMID: 37509426 Free PMC article.
References
-
- Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A, International Breast Cancer Study Group T (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23–01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 19:1385–1393. https://doi.org/10.1016/S1470-2045(18)30380-2 - DOI - PubMed
-
- Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318:918–926. https://doi.org/10.1001/jama.2017.11470 - DOI - PubMed - PMC
-
- Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575. https://doi.org/10.1001/jama.2011.90 - DOI - PubMed - PMC
-
- Gentilini O, Botteri E, Dadda P, Sangalli C, Boccardo C, Peradze N, Ghisini R, Galimberti V, Veronesi P, Luini A, Cassano E, Viale G, Veronesi U (2016) Physical function of the upper limb after breast cancer surgery. Results from the SOUND (sentinel node vs. Observation after axillary Ultra-souND) trial. Eur J Surg Oncol 42:685–689. https://doi.org/10.1016/j.ejso.2016.01.020 - DOI - PubMed
-
- Rao R, Euhus D, Mayo HG, Balch C (2013) Axillary node interventions in breast cancer: a systematic review. JAMA 310:1385–1394. https://doi.org/10.1001/jama.2013.277804 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical